In a welcome move, Smith & Nephew ADR saw its Relative Strength Rating rise from 69 to 73 on Wednesday.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks often have an 80 or better RS Rating in the early stages of their moves. See if Smith & Nephew ADR can continue to show renewed price strength and clear that threshold.
Smith & Nephew ADR is building a consolidation with a 31.72 buy point. See if the stock can break out in heavy trading.
The company posted -2% EPS growth last quarter. Revenue gains came in at 6%. The next quarterly results are expected on or around Aug. 5.
Smith & Nephew ADR holds the No. 20 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
